Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or at another non-clinic location, if available. The total study duration is up to 24 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed SARS-CoV-2 infection 5 days prior to randomization
Initial onset of COVID-19 signs/symptoms within 5 days of randomization
Fertile participants must agree to use a highly effective method of contraception
You may not be if
Has at least one underlying medical condition associated with an increased risk of developing severe illness from COVID-19
History of or need for hospitalization for the medical treatment of COVID-19
Prior diagnosis of SARS-CoV-2 infection (reinfection)
Known medical history of liver disease
Receiving dialysis or have known renal impairment
Known Human Immunodeficiency Virus (HIV) infection with viral load \> 400 copies/ml or taking prohibited medications for HIV treatment
Suspected or confirmed concurrent active systemic infection other than COVID-19
Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4
Has received or is expected to receive monoclonal antibody treatment or convalescent COVID-19 plasma
Has received any SARS-CoV-2 vaccine within 12 months of screening
Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19
Known prior participation in this trial or other trial involving PF-07321332
